Nicoletta Bivi
0000-0003-1238-3822
Eli Lilly and Co
3 papers found
Refreshing results…
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
The method history report: an adaptable tool for communicating immunogenicity assay development and validation
Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
Missing publications? Search for publications with a matching author name.